Keitaro Iida

Luteolin suppresses bladder cancer growth via regulation of mechanistic target of rapamycin pathway

Keitaro Iida, Taku Naiki, Aya Naiki‐Ito et al. · Cancer Science · 2020 · 88 citations · Full text

Medicine, Oncology, Pharmacology +16

Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer

Aya Naiki‐Ito, Taku Naiki, Hiroyuki Kato et al. · Carcinogenesis · 2019 · 56 citations · Full text

Medicine, Cancer Biology, Pharmacology +17

NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect

Toshiki Etani, Takayoshi Suzuki, Taku Naiki et al. · Oncotarget · 2014 · 46 citations · Full text

Medicine, Oncology, Pharmacology +17

Low Geriatric Nutritional Risk Index as a Poor Prognostic Marker for Second-Line Pembrolizumab Treatment in Patients with Metastatic Urothelial Carcinoma: A Retrospective Multicenter Analysis

Toshiki Etani, Taku Naiki, Yosuke Sugiyama et al. · Oncology · 2020 · 29 citations

Medicine, Oncology, Pharmacology +17

GPX2 promotes development of bladder cancer with squamous cell differentiation through the control of apoptosis

Taku Naiki, Aya Naiki‐Ito, Keitaro Iida et al. · Oncotarget · 2018 · 28 citations · Full text

Medicine, Cancer Biology, Oncology +16